| Patents for A61P 1 - Drugs for disorders of the alimentary tract or the digestive system (125,798) |
|---|
| 02/28/2001 | CN1285194A Crustaceous extract health care foods and preparation method thereof |
| 02/28/2001 | CN1062555C Substituted benzyloxy carbonyl guanidine, its prepn. method, and application of the same as medicament and medicament containing the same |
| 02/28/2001 | CN1062478C Medical extract for treating constipation |
| 02/28/2001 | CN1062470C Chinese medicine prepn. for infant anorexia |
| 02/28/2001 | CN1062463C Oral liquid for smoothing liver and normalizing gallbladder |
| 02/28/2001 | CN1062462C Medicine for treatment of ranal lighiasis, liver and gall lithiasis |
| 02/28/2001 | CN1062455C Method for preparation of gargle of sarcandra glabra |
| 02/28/2001 | CN1062443C Medicinal oral cavity fragrant liquid for curing halitosis |
| 02/28/2001 | CA2317001A1 Process for making 5-lipoxygenase inhibitors having varied heterocyclic ring systems |
| 02/27/2001 | USRE37078 Antiinflammatory agents, antiarthritic agents |
| 02/27/2001 | US6194462 Pharmaceutical preparation containing nimesulide for oral administration |
| 02/27/2001 | US6194458 1-(2-methoxyphenyl)-1-oxo-2-aza-(s)-4-i-butyl-4-phenylbutane, for example; treating various conditions including transplantation rejection of organs or tissues in a patient; immunosuppressant compositions |
| 02/27/2001 | US6194449 Allosteric adenosine receptor modulators |
| 02/27/2001 | US6194448 N, N-disubstituted amides that inhibit the binding of integrins to their receptors |
| 02/27/2001 | US6194437 Non-peptide bombesin receptor antagonists |
| 02/27/2001 | US6194405 3,3a,8,12b-tetrahydro-n-methyl-2h-dibenzo(3,4:6,7)-cyclohepta( 1,2-b)-furan-2-methanamine, for example; anxiolytic agents, antidepressants, sleep and sexual disorders, psychological, cardiovascular and gastrointestinal disorders |
| 02/27/2001 | US6194208 Modified milk growth factor |
| 02/27/2001 | US6194020 Conserving procyanidins(catechins); candy |
| 02/27/2001 | US6194004 Dry mix formulation for bisphosphonic acids |
| 02/27/2001 | US6193994 Locally administrable, biodegradable and sustained-release pharmaceutical composition for periodontitis and process for preparation thereof |
| 02/27/2001 | CA2316662A1 Use of crf antagonists and related compositions |
| 02/27/2001 | CA2316647A1 Treatment or prevention of coccidiosis |
| 02/27/2001 | CA2191230C 2-halo-2'-deoxyadenosine treatment for inflammatory bowel disease |
| 02/27/2001 | CA2025598C Chimaeric hepadnavirus core antigen proteins |
| 02/22/2001 | WO2001012819A2 Protein phosphatases and diagnosis and treatment of phosphatase-related disorders |
| 02/22/2001 | WO2001012797A2 Method of separating rotavirus variants and live attenuated rotavirus vaccine |
| 02/22/2001 | WO2001012790A2 Isomerase proteins |
| 02/22/2001 | WO2001012786A1 Retinoid receptor interacting polynucleotides, polypeptides, and antibodies |
| 02/22/2001 | WO2001012781A1 13 human colon and colon cancer associated proteins |
| 02/22/2001 | WO2001012775A2 25 human secreted proteins |
| 02/22/2001 | WO2001012671A1 Human tumor necrosis factor receptor tr16 |
| 02/22/2001 | WO2001012670A1 Tgf-beta receptor polynucleotides, polypeptides, and antibodies |
| 02/22/2001 | WO2001012662A2 Membrane associated proteins |
| 02/22/2001 | WO2001012633A1 Water soluble sdz-rad esters |
| 02/22/2001 | WO2001012621A1 INHIBITORS OF c-JUN N-TERMINAL KINASES (JNK) AND OTHER PROTEIN KINASES |
| 02/22/2001 | WO2001012618A1 Dihydroaminobenzo[b]- and [c]furans as retinoid-like agents |
| 02/22/2001 | WO2001012611A1 Pyrimidine-2,4,6-trione metalloproteinase inhibitors |
| 02/22/2001 | WO2001012606A2 Tetrahydroquinoline derivatives having retinoid-like biological activity |
| 02/22/2001 | WO2001012603A1 Indole derivatives, process for their preparation, pharmaceutical compositions containing them and their medicinal application |
| 02/22/2001 | WO2001012602A1 Condensed indoline derivatives and their use as 5ht, in particular 5ht2c, receptor ligands |
| 02/22/2001 | WO2001012598A2 METHODS OF INHIBITING BINDING OF β-SHEET FIBRIL TO RAGE AND CONSEQUENCES THEREOF |
| 02/22/2001 | WO2001012592A2 Hydroxamic acid compounds useful as matrix metalloproteinase inhibitors |
| 02/22/2001 | WO2001012584A2 Pharmaceutical compounds |
| 02/22/2001 | WO2001012567A1 A glass composition |
| 02/22/2001 | WO2001012550A1 POLYTYPE Mg-Al HYDROTALCITE |
| 02/22/2001 | WO2001012264A2 Topical azathioprine for the treatment of oral autoimmune diseases |
| 02/22/2001 | WO2001012233A2 Sustained release formulation of a peptide |
| 02/22/2001 | WO2001012227A1 Nsaid and efgr kinase inhibitor containing composition for the treatment or inhibition of colonic polyps and colorectal cancer |
| 02/22/2001 | WO2001012222A1 Immunological tolerance-induction agent |
| 02/22/2001 | WO2001012214A2 MYCOPHENOLATE MOFETIL IN ASSOCIATION WITH PEG-IFN-$g(a) |
| 02/22/2001 | WO2001012193A1 Pharmaceutical agent comprising a benzamide derivative as active ingredient |
| 02/22/2001 | WO2001012186A1 Cell adhesion inhibitors |
| 02/22/2001 | WO2001012181A1 Improved topical medicaments and methods for photodynamic treatment of disease |
| 02/22/2001 | WO2001012155A1 Compositions and methods for enhanced absorption of hydrophilic therapeutic agents |
| 02/22/2001 | WO2000077179A3 Human poly(adp-ribose) polymerase 2 materials and methods |
| 02/22/2001 | WO2000071538A3 1-trifluoromethyl-4-hydroxy-7-piperidinyl-aminomethylchroman derivatives |
| 02/22/2001 | WO2000071514A8 α-AMINO-β-SULFONYL HYDROXAMIC ACID COMPOUNDS |
| 02/22/2001 | WO2000069470A3 Improved cellular uptake of bioactive agents |
| 02/22/2001 | DE19939463A1 Tryptase inhibitors useful e.g. for treating inflammatory or allergic disease, arteriosclerosis or neoplasia, comprising new or known 2-phenethyl-benzimidazole-5-carboxamides |
| 02/22/2001 | CA2698353A1 Pharmaceutical compounds |
| 02/22/2001 | CA2391319A1 Water soluble sdz-rad esters |
| 02/22/2001 | CA2385487A1 13 human colon and colon cancer associated proteins |
| 02/22/2001 | CA2385431A1 Tgf-beta receptor polynucleotides, polypeptides, and antibodies |
| 02/22/2001 | CA2383691A1 Human tumor necrosis factor receptor tr16 |
| 02/22/2001 | CA2383268A1 Pyrazoloanthrone and derivatives thereof as jnk inhibitors and their compositions |
| 02/22/2001 | CA2382749A1 Amines substituted with a dihydro-isobenzofuranyl group, an aryl or heteroaryl group and an alkyl group, having retinoid-like biological activity |
| 02/22/2001 | CA2382148A1 25 human secreted proteins |
| 02/22/2001 | CA2382095A1 Methods of inhibiting binding of .beta.-sheet fibril to rage and consequences thereof |
| 02/22/2001 | CA2382019A1 Isomerase proteins |
| 02/22/2001 | CA2382018A1 Retinoid receptor interacting polynucleotides, polypeptides, and antibodies |
| 02/22/2001 | CA2382015A1 Membrane associated proteins |
| 02/22/2001 | CA2381971A1 Amines substituted with a tetrahydroquinolinyl group, an aryl or heteroaryl group and an alkyl group, having retinoid-like biological acitity |
| 02/22/2001 | CA2381551A1 Pyrimidine-2,4,6-trione metalloproteinase inhibitors |
| 02/22/2001 | CA2381409A1 Nitric ester derivatives |
| 02/22/2001 | CA2381287A1 Polytype mg-ai hydrotalcite |
| 02/22/2001 | CA2380817A1 Cell adhesion inhibitors |
| 02/22/2001 | CA2380653A1 Mycophenolate mofetil in association with peg-ifn-.alpha. |
| 02/22/2001 | CA2380642A1 Compositions and methods for enhanced absorption of hydrophilic therapeutic agents |
| 02/22/2001 | CA2379196A1 Rotavirus vaccine formulations |
| 02/22/2001 | CA2378332A1 Hydroxamic acid compounds useful as matrix metalloproteinase inhibitors |
| 02/22/2001 | CA2377662A1 Novel protein phosphatases and diagnosis and treatment of phosphatase-related disorders |
| 02/22/2001 | CA2377646A1 Indole derivatives, process for their preparation, pharmaceutical compositions containing them and their medicinal application |
| 02/22/2001 | CA2377637A1 Condensed indoline derivatives and their use as 5ht, in particular 5ht2c, receptor ligands |
| 02/21/2001 | EP1077068A1 Utilization of interferon alpha 5 in the treatment of viral hepatopathies |
| 02/21/2001 | EP1077061A2 Use of peroxidised lipids for treating or preventing mucosal wounds and inflammations of the oral cavity |
| 02/21/2001 | EP1076700A2 Human nucleic acid sequences obtained from pancreas tumor tissue |
| 02/21/2001 | EP1076696A2 Human receptor molecules |
| 02/21/2001 | EP1076659A1 Paroxetine 10-camphorsulfonate for treatment of cns disorders |
| 02/21/2001 | EP1076650A1 Aryl fused azapolycyclic compounds |
| 02/21/2001 | EP1076641A1 Inhibitors of impdh enzyme |
| 02/21/2001 | EP1076563A1 Dipeptide caspase inhibitors and the use thereof |
| 02/21/2001 | EP1076557A1 Ccr-3 receptor antagonists |
| 02/21/2001 | CN1284997A Modified deacetoxycephalosporin C synthase (DAOCS) and x-ray structure |
| 02/21/2001 | CN1284951A Triazine compounds for treatment of CNS disorders |
| 02/21/2001 | CN1284947A Carboxyl acid substituted heterocycles as metalloproteinase inhibitors |
| 02/21/2001 | CN1284942A Matrix metalloprotease inhibitors |
| 02/21/2001 | CN1284877A Gastroprotected omerprazole microgranules, method for obtaining same and pharmaceutical preparations |
| 02/21/2001 | CN1284874A 5-HT1F agonists |
| 02/21/2001 | CN1284869A Treatment of chronic inflammatory disorders of gastrointestinal tract |
| 02/21/2001 | CN1284868A Oral pharmaceutical pulsed release dosage form |